01.27.26 -- A Deeper Look At Pharma's Structural Supply Chain Vulnerability

To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.

See how proactively designing around plant constraints, using high-capacity resins, and leveraging parallel workstreams resulted in a 50% reduction in processing hours and 25% lower costs.

Consider this manufacturing platform integrating perfusion bioreactors, continuous product capture, low pH viral inactivation, polishing, viral filtration, and formulation steps.

When using CRISPR-Cas proteins for gene editing, it’s critical to ensure consistency and quality. The FDA recommends establishing well-defined acceptance criteria for the RNP formation step.

Learn how outsourcing cell culture media and buffers removes bottlenecks, freeing specialized CDMO resources. Ensure consistency, accelerate timelines, and streamline GMP readiness for client success.

Controlled nucleation standardizes freezing across all vials, leading to uniform ice crystals and improved lyo cake quality. This critical step reduces variability and supports robust product scale-up.

Explore an advanced electroporation platform that enables reliable, large-scale, non-viral delivery of complex gene editing tools like CRISPR/Cas9 for T-cell manufacturing.

Stability testing is essential to ensuring your drug’s stability, potency, efficacy, and safety under different controlled conditions throughout development, manufacturing, and life cycle management.

Examine the 3 phases of sterile injectable project tech transfer, including how to bridge information gaps and facilitate successful regulatory filing at this fundamental stage of drug development.

Standardized, continuously optimized facility design enables scalable and reliable biomanufacturing that improves quality, accelerates timelines, and ensures consistent performance across sites.